Treanda (Bendamustine) for Myeloma | MyMyelomaTeam

Connect with others who understand.

sign up Log in
About MyMyelomaTeam
Powered By

Treanda is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Treanda is sometimes prescribed as part of a chemotherapy regimen in combination with other drugs for people with myeloma. Treanda is also known by its drug name, bendamustine.

Treanda is an anti-cancer drug used in chemotherapy. Treanda is a member of a class of drugs called alkylating agents. Treanda is believed to work by preventing the production of DNA in cells, thereby blocking cancer cell division.

How do I take it?
Treanda is administered as an intravenous infusion during chemotherapy treatment.

Side effects
The FDA-approved label for Treanda lists common side effects including fatigue, fever, mouth sores, nausea, vomiting, diarrhea, constipation, rash, loss of appetite, weight loss, cough, headache, increased risk for infection, and anemia.

Rare but serious side effects listed for Treanda include severe skin reactions, liver damage, increased risk for other types of cancer, tumor lysis syndrome, hypersensitivity reactions, and fetal harm in pregnant women.

For more details about this treatment, visit:

Treanda — Cephalon

Drug Therapy for Multiple Myeloma — American Cancer Society

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in